Autologous bone marrow transplantation for the treatment of multiple sclerosis

Current Neurology and Neuroscience Reports

Volumn 14, Issue 9, 2014, Pages

  Radaelli, Marta ^a   Merlini, Arianna ^a,b   Greco, Raffaella ^b   Sangalli, Francesca ^a   Comi, Giancarlo ^a   Ciceri, Fabio ^b   Martino, Gianvito ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Autoimmunity; Autologous Hematopoietic stem cell transplantation; Cell therapy; Immunosuppression; Multiple Sclerosis; Multiple sclerosis treatment

Indexed keywords

ARTICLE; AUTOIMMUNE THYROIDITIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEASIBILITY STUDY; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MULTIPLE SCLEROSIS; NONHUMAN; PATIENT SAFETY; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; SEPSIS; STEM CELL MOBILIZATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; VIRUS REACTIVATION; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; PROCEDURES;

BONE MARROW TRANSPLANTATION; HUMANS; MULTIPLE SCLEROSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84904271569     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-014-0478-0     Document Type: Article

References (50)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938-52. doi:10.1056/NEJM200009283431307.
2. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606-16. doi:10.1093/brain/awl007. (Pubitemid 43278223)
3. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain. 1999;122(Pt 10):1941-50.
4. Codarri L, Greter M, Becher B. Communication between pathogenic T-cells and myeloid cells in neuroinflammatory disease. Trends Immunol. 2013;34(3):114-9. doi:10.1016/j.it.2012.09.007.
5. Comi G. Induction vs escalating therapy in multiple sclerosis: practical implications. Neurol Sci. 2008;29 Suppl 2:S253-5. doi:10.1007/s10072-008-0954-x .
6. Saccardi R, Di Gioia M, Bosi A. Haematopoietic stem cell transplantation for autoimmune disorders. Curr Opin Hematol. 2008;15(6):594-600. doi:10.1097/MOH.0b013e3283136700.
7. •• Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47(6):770-90. doi:10.1038/bmt.2011.185. Current guidelines for HSCT in autoimmune disorders.
8. van Bekkum DW. Stem cell transplantation in experimental models of autoimmune disease. J Clin Immunol. 2000;20(1):10-6.
9. Marmont AM. Stem cell transplantation for autoimmune disorders. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Hematol. 2004;17(2): 223-32. doi:10.1016/j.beha.2004.04.004. (Pubitemid 39145095)
10. Burt RK, Padilla J, Begolka WS, Canto MC, Miller SD. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood. 1998;91(7):2609-16. (Pubitemid 28155538)
11. Pfender N, Saccardi R, Martin R. Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr Treat Options Neurol. 2013;15(3):270-80. doi:10.1007/s11940-013-0234-9.
12. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201(5):805-16. doi:10.1084/jem.20041679. (Pubitemid 40395124)
13. • Darlington PJ, Touil T, Doucet JS, Gaucher D, Zeidan J, Gauchat D, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol. 2013;73(3):341-54. doi:10.1002/ana.23784. Observation that HSCT selectively reduces Th17 in MS.
14. Dubinsky AN, Burt RK, Martin R, Muraro PA. T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34+ selected graft. Bone Marrow Transplant. 2010;45(2):325-31. doi:10.1038/bmt.2009.139.
15. Muraro PA, Robins H, Malhotra S, Howell M, Phippard D, Desmarais C, et al. T-cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest. 2014;124(3):1168-72. doi:10.1172/JCI71691.
16. • Abrahamsson SV, Angelini DF, Dubinsky AN, Morel E, Oh U, Jones JL, et al. Nonmyeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T-cells in multiple sclerosis. Brain. 2013;136(Pt 9):2888-903. doi:10.1093/brain/awt182. Mechanism of action of nonmyeloablative conditioning in HSCT for MS.
17. Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive Tcells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004;127(Pt 5):996-1008. doi:10.1093/brain/awh117. (Pubitemid 38623037)
18. Cassiani-Ingoni R, Muraro PA, Magnus T, Reichert-Scrivner S, Schmidt J, Huh J, et al. Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J Neuropathol Exp Neurol. 2007;66(7):637-49. doi:10.1097/nen. 0b013e318093f3ef. (Pubitemid 47051709)
19. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain. 2007;130(Pt 5):1254-62. doi:10.1093/brain/awl370. (Pubitemid 47355940)
20. Lu JQ, Joseph JT, Nash RA, Storek J, Stevens AM, Metz LM, et al. Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation. Arch Neurol. 2010;67(6):716-22. doi:10.1001/archneurol.2010.117.
21. Lu JQ, Storek J, Metz L, Yong VW, Stevens AM, Nash RA, et al. Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch Neurol. 2009;66(1):116-20. doi:10.1001/archneurol.2008.522.
22. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1997;20(8):631-8. doi:10.1038/sj.bmt.1700944. (Pubitemid 27477575)
23. Comi G, Kappos L, Clanet M, Ebers G, Fassas A, Fazekas F, et al. Guidelines for autologous blood and marrow stem cell transplantation inmultiple sclerosis: a consensus reportwritten on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. BMT-MS Study Group. J Neurol. 2000;247(5):376-82. (Pubitemid 30364617)
24. Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 2003;102(7):2373-8. doi:10.1182/blood-2003-03-0877. (Pubitemid 37193572)
25. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003;102(7):2364-72. doi:10.1182/blood-2002-12-3908. (Pubitemid 37193571)
26. Kozak T, Havrdova E, Pit'ha J, Gregora E, Pytlik R, Maaloufova J, et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant. 2000;25(5):525-31. doi:10.1038/sj.bmt.1702180. (Pubitemid 30137868)
27. Samijn JP, te Boekhorst PA, Mondria T, van Doorn PA, Flach HZ, van der Meche FG, et al. Intense T-cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(1):46-50. doi:10.1136/jnnp.2005.063883. (Pubitemid 43022689)
28. Openshaw H, Lund BT, Kashyap A, Atkinson R, Sniecinski I, Weiner LP, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant. 2000;6(5A):563-75.
29. Saiz A, Blanco Y, Carreras E, Berenguer J, Rovira M, Pujol T, et al. Clinical and MRI outcome after autologous hematopoietic stemcell transplantation in MS. Neurology. 2004;62(2):282-4. (Pubitemid 38167140)
30. Shevchenko JL, Kuznetsov AN, Ionova TI, Melnichenko VY, Fedorenko DA, Kartashov AV, et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol. 2012;40(11):892-8. doi:10.1016/j.exphem.2012.07.003.
31. Shevchenko YL, Novik AA, Kuznetsov AN, Afanasiev BV, Lisukov IA, Kozlov VA, et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol. 2008;36(8):922-8. doi:10.1016/j.exphem.2008.03.001.
32. • Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP, et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-center experience. Mult Scler. 2012;18(6):835- 42. doi:10.1177/ 1352458511429320. Italian study of autologous HSCT in MS with BEAM/ATG conditioning regimen.
33. Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry. 2014. doi:10.1136/jnnp-2013-307207.
34. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/ II study. Lancet Neurol. 2009;8(3):244-53. doi:10.1016/S1474-4422(09)70017-1.
35. Chen B, Zhou M, Ouyang J, Zhou R, Xu J, Zhang Q, et al. Longterm efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol Sci. 2012;33(4):881-6. doi:10.1007/s10072-011-0859-y.
36. Fagius J, Lundgren J, Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler. 2009;15(2):229-37. doi:10.1177/1352458508096875.
37. Xu J, Ji BX, Su L, Dong HQ, Sun XJ, Liu CY. Clinical outcomes after autologous haematopoietic stemcell transplantation in patients with progressive multiple sclerosis. Chin Med J (Engl). 2006;119(22):1851-5. (Pubitemid 44816860)
38. Krasulova E, Trneny M, Kozak T, Vackova B, Pohlreich D, Kemlink D, et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single center 10-year experience. Mult Scler. 2010;16(6):685-93. doi:10.1177/1352458510364538.
39. Hamerschlak N, Rodrigues M, Moraes DA, Oliveira MC, Stracieri AB, Pieroni F, et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/ horse ATG and CY/rabbit ATG. Bone Marrow Transplant. 2010;45(2):239-48. doi:10.1038/bmt.2009.127.
40. Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol. 2002;249(8):1088-97. doi:10.1007/s00415-002-0800-7. (Pubitemid 35002235)
41. •• Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.Mult Scler. 2012;18(6):825-34. doi:10.1177/1352458512438454. Proposed indications for HSCT in MS patients: patient's selection, procedures, and outcome assessment.
42. Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology. 2000;54(11):2147-50. (Pubitemid 30397217)
43. •• Fassas A, Kimiskidis VK, Sakellari I, Kapinas K, Anagnostopoulos A, Tsimourtou V, et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology. 2011;76(12): 1066-70. doi:10.1212/WNL.0b013e318211c537. Outcome of HSCT in MS patients after a median follow-up of 11 years.
44. Bowen JD, Kraft GH, Wundes A, Guan Q, Maravilla KR, Gooley TA, et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant. 2012;47(7):946-51. doi:10.1038/bmt.2011.208.
45. Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E, et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler. 2006;12(6):814-23. (Pubitemid 46111776)
46. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, et al. Autologous stem cell transplantation in progressive multiple sclerosis-an interim analysis of efficacy. J Clin Immunol. 2000;20(1):24-30. (Pubitemid 30210103)
47. Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P, et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood. 2005;105(6):2601-7. doi:10.1182/blood-2004-08-3205. (Pubitemid 40387065)
48. Mancardi GL, Murialdo A, Rossi P, Gualandi F, Martino G, Marmont A, et al. Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler. 2005;11(3):367-71. (Pubitemid 40775198)
49. • Reston JT, Uhl S, Treadwell JR, Nash RA, Schoelles K. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler. 2011;17(2):204-13. doi:10.1177/1352458510383609. An updated review and meta-analysis of autologous HSCT studies in MS.
50. Muraro PA, Douek DC. Renewing the T-cell repertoire to arrest autoimmune aggression. Trends Immunol. 2006;27(2):61-7. doi:10.1016/j.it.2005.12.003. (Pubitemid 43221971)